Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 CAR T Cells With or Without NKTR-255 in B Cell Malignancies
NCT03233854Phase 1Active, not recruiting
- Sponsor
- Stanford University
- Start
- Sep 2017
- Primary completion
- Jun 2023
- Modality
- Gene Editing, Polymer-based Nanoparticles, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AUTO1/22 and NKTR-255 in B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL), sponsored by Stanford University. Primary endpoints: Incidence and severity of dose limiting toxicities up to 28 days, Maximum tolerated dose of CD19/CD22 CAR T cells up to 28 days and 1 more. Started Sep 2017; status: active, not recruiting.
02
Drugs
AUTO1/22NKTR-255
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03233854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03233854.